“Growing Adoption of Long-Acting Drug Delivery Systems in Macular Degeneration Treatment”
- A significant trend in the Global Macular Degeneration Treatment Market is the growing adoption of long-acting drug delivery systems designed to extend treatment duration and reduce the frequency of intravitreal injections. These systems aim to improve patient adherence and quality of life by maintaining therapeutic drug levels over extended periods, thus minimizing the treatment burden commonly associated with age-related macular degeneration (AMD).
- For instance, Genentech (a member of the Roche Group) has developed the Susvimo™ (ranibizumab injection) Port Delivery System, an implantable, refillable device that continuously delivers ranibizumab to the eye for up to six months. This innovation offers a significant advancement over monthly injections, reducing treatment fatigue and improving real-world outcomes in patients with wet AMD.
- These next-generation delivery methods, including ocular implants, sustained-release injectables, and hydrogel-based systems, provide targeted and consistent drug release. By maintaining stable intraocular drug levels, they enhance treatment efficacy and reduce the risk of undertreatment or disease progression between doses.
- Moreover, the integration of biologics like anti-VEGF agents with long-acting delivery technologies is reshaping the standard of care. Such combinations not only ensure precise action at the disease site but also support individualized treatment intervals based on patient needs and disease activity.
- This trend toward long-acting delivery systems reflects a broader shift in macular degeneration care—toward more patient-friendly, outcome-driven therapies. As companies continue investing in sustained-release innovations, these technologies are expected to play a pivotal role in expanding treatment accessibility, optimizing clinical outcomes, and driving long-term growth in the Global Macular Degeneration Treatment Market.
